4d Molecular Therapeutics Stock Performance
| FDMT Stock | USD 7.62 0.17 2.18% |
The firm owns a Beta (Systematic Risk) of -0.33, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning 4D Molecular are expected to decrease at a much lower rate. During the bear market, 4D Molecular is likely to outperform the market. At this point, 4D Molecular Therapeutics has a negative expected return of -1.01%. Please make sure to confirm 4D Molecular's information ratio, as well as the relationship between the potential upside and rate of daily change , to decide if 4D Molecular Therapeutics performance from the past will be repeated sooner or later.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days 4D Molecular Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's primary indicators remain comparatively stable which may send shares a bit higher in December 2024. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
Actual Historical Performance (%)
One Day Return (0.51) | Five Day Return (11.43) | Year To Date Return (63.53) | Ten Year Return (80.86) | All Time Return (80.86) |
1 | Acquisition by Kirn David of 11653 shares of 4D Molecular at 14.42 subject to Rule 16b-3 | 09/04/2024 |
2 | 4d Molecular Therapeutics executive sells 8.2k in stock | 09/18/2024 |
3 | Shareholders Are Encouraged To Join The Schall Law Firms Inquiry Into 4D Molecular Therapeutics Inc For Securities Related Infractions | 10/03/2024 |
4 | The Schall Law Firm Urges Investor Participation In An Investigation Into 4D Molecular Therapeutics Inc For Securities Fraud | 10/16/2024 |
5 | Shareholders Are Encouraged To Join An Inquiry Into 4D Molecular Therapeutics, Inc. For Securities Law Violations | 10/25/2024 |
6 | Vanguard Group Incs Strategic Acquisition of Shares in 4D Molecular Therapeutics Inc | 11/05/2024 |
7 | Disposition of 240000 shares by Bvf Partners L Pil of 4D Molecular subject to Rule 16b-3 | 11/08/2024 |
8 | 4D Molecular Therapeutics Inc Reports Q3 2024 EPS of and Revenue of 3,000 | 11/13/2024 |
9 | Deep Track Capital, LP Increases Stake in 4D Molecular Therapeutics Inc | 11/14/2024 |
10 | 4D Molecular initiated by Morgan Stanley at underweight | 11/21/2024 |
| Begin Period Cash Flow | 52.4 M |
FDMT |
4D Molecular Relative Risk vs. Return Landscape
If you would invest 1,530 in 4D Molecular Therapeutics on August 28, 2024 and sell it today you would lose (768.00) from holding 4D Molecular Therapeutics or give up 50.2% of portfolio value over 90 days. 4D Molecular Therapeutics is currently does not generate positive expected returns and assumes 4.1166% risk (volatility on return distribution) over the 90 days horizon. In different words, 36% of stocks are less volatile than FDMT, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
4D Molecular Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for 4D Molecular's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as 4D Molecular Therapeutics, and traders can use it to determine the average amount a 4D Molecular's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.2459
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | FDMT |
Estimated Market Risk
| 4.12 actual daily | 36 64% of assets are more volatile |
Expected Return
| -1.01 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.25 actual daily | 0 Most of other assets perform better |
Based on monthly moving average 4D Molecular is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of 4D Molecular by adding 4D Molecular to a well-diversified portfolio.
4D Molecular Fundamentals Growth
FDMT Stock prices reflect investors' perceptions of the future prospects and financial health of 4D Molecular, and 4D Molecular fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on FDMT Stock performance.
| Return On Equity | -0.24 | ||||
| Return On Asset | -0.17 | ||||
| Current Valuation | (116.94 M) | ||||
| Shares Outstanding | 46.23 M | ||||
| Price To Book | 0.65 X | ||||
| Price To Sales | 21,183 X | ||||
| Revenue | 20.72 M | ||||
| Gross Profit | (77.12 M) | ||||
| EBITDA | (107.12 M) | ||||
| Net Income | (100.84 M) | ||||
| Cash And Equivalents | 241.09 M | ||||
| Cash Per Share | 7.45 X | ||||
| Total Debt | 14.67 M | ||||
| Debt To Equity | 0.06 % | ||||
| Current Ratio | 17.20 X | ||||
| Book Value Per Share | 7.15 X | ||||
| Cash Flow From Operations | (75.79 M) | ||||
| Earnings Per Share | (2.85) X | ||||
| Market Capitalization | 360.11 M | ||||
| Total Asset | 339.89 M | ||||
| Retained Earnings | (415.33 M) | ||||
| Working Capital | 277.64 M | ||||
About 4D Molecular Performance
Assessing 4D Molecular's fundamental ratios provides investors with valuable insights into 4D Molecular's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the 4D Molecular is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (626.16) | (657.47) | |
| Return On Tangible Assets | (0.30) | (0.31) | |
| Return On Capital Employed | (0.35) | (0.37) | |
| Return On Assets | (0.30) | (0.31) | |
| Return On Equity | (0.33) | (0.31) |
Things to note about 4D Molecular Therapeutics performance evaluation
Checking the ongoing alerts about 4D Molecular for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for 4D Molecular Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| 4D Molecular generated a negative expected return over the last 90 days | |
| 4D Molecular has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 20.72 M. Net Loss for the year was (100.84 M) with loss before overhead, payroll, taxes, and interest of (77.12 M). | |
| 4D Molecular Therapeutics currently holds about 241.09 M in cash with (75.79 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.45. | |
| 4D Molecular has a poor financial position based on the latest SEC disclosures | |
| Over 96.0% of the company shares are owned by institutional investors | |
| Latest headline from seekingalpha.com: 4D Molecular initiated by Morgan Stanley at underweight |
- Analyzing 4D Molecular's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether 4D Molecular's stock is overvalued or undervalued compared to its peers.
- Examining 4D Molecular's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating 4D Molecular's management team can have a significant impact on its success or failure. Reviewing the track record and experience of 4D Molecular's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of 4D Molecular's stock. These opinions can provide insight into 4D Molecular's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for FDMT Stock Analysis
When running 4D Molecular's price analysis, check to measure 4D Molecular's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy 4D Molecular is operating at the current time. Most of 4D Molecular's value examination focuses on studying past and present price action to predict the probability of 4D Molecular's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move 4D Molecular's price. Additionally, you may evaluate how the addition of 4D Molecular to your portfolios can decrease your overall portfolio volatility.